Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users
Combination of 0.09% Cyclosporine and Intense Pulsed Light (IPL) Therapy for the Treatment of Dry Eye Disease in Symptomatic Contact Lens Wearers: a Sham-Controlled Randomized Clinical Trial
Université de Sherbrooke
44 participants
Apr 25, 2024
INTERVENTIONAL
Conditions
Summary
In this study, two treatments typically used for dry eye disease will be tried for contact lens users to see if their symptoms when they use their contact lenses get better. Cyclosporine is a drop that is used for long-term management of the inflammation and Intense pulsed light (IPL) is a treatment done in a clinic to improve the health of the eyelid glands. The main question in this study is: Does the combined treatment of cyclosporine and IPL improve the symptoms and the dry eye signs of contact lens wearers? All the participants will receive the cyclosporine drops for 4 months twice a day. The research team will split the group of participants in two, half receiving the real IPL treatment and half receiving a sham IPL treatment during the last two months of the study. This will allow to compare the two groups to see how IPL helped. The dry eye tests will be done at the start of the study, after two months and after 4 months. The tests will include a dry eye symptoms questionnaire, measures on the tears, the structures of the front of the eye and the eyelids.
Eligibility
Inclusion Criteria4
- Soft silicone-hydrogel contact lens wearers
- Monthly, 2-weeks, opr daily replacement schedule of contact lens
- Minimum wear of contact lens for 1 day/week and 4 hours consecutive
- f-CLDEQ-8 score ≥ 12
Exclusion Criteria16
- Past usage of cyclosporine 0.09% (Cequa)
- Use of another ophthalmic cyclosporine drop in the past 6 months
- Known intolerance to cyclosporine
- Pregnancy or breastfeeding (or planned pregnancy in the duration study)
- History of ocular herpes simplex infection
- Active ocular infectious condition
- Usage of photosensitizing medication
- Epilepsy
- History of skin cancer in the IPL treatment zone
- Tattoo/pigmented lesion/keloid scars in the IPL treatment zone
- Refractive surgery in the past 12 months
- In-clinic thermal pulsation eyelid treatment in the past 12 months
- Usage of glaucoma drops
- Regular continuous wear of contact lenses (including sleep)
- Excessive movement or decentration of the contact lenses (assessed at first visit)
- Giant papillary conjunctivitis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06392438